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The targeted migration of neural stem/progenitor cells (NSPCs) is a prerequisite for the use of stem cell therapy in
the treatment of pathologies. This migration is regulated mainly by C-X-C motif chemokine 12 (CXCL12).
Therefore, promotion of the migratory responses of grafted cells by upregulating CXCL12 signaling has been
proposed as a strategy for improving the efficacy of such cell therapies. However, the effects of this strategy on
brain tumors have not yet been examined in vivo. The aim of the present study was thus to elucidate the effects
of grafted rat green fluorescent protein (GFP)–labeled NSPCs (GFP-NSPCs) with CXCL12 enhancement on a
model of spontaneous rat brain tumor induced by N-ethyl-N-nitrosourea. T2-weighted magnetic resonance
imaging was applied to determine the changes in tumor volume and morphology over time. Postmortem
histology was performed to confirm the tumor pathology, expression levels of CXCL12 and C-X-C chemokine
receptor type 4, and the fate of GFP-NSPCs. The results showed that the tumor volume and hypointense areas of
T2-weighted images were both significantly increased in animals treated with combined NSPC transplantation
and CXCL12 induction, but not in control animals or in those with tumors that received only one of the
treatments. GFP-NSPCs appear to migrate toward tumors with CXCL12 enhancement and differentiate uniquely
into a neuronal lineage. These findings suggest that CXCL12 is an effective chemoattractant that facilitates
exogenous NSPC migration toward brain tumors and that CXCL12 and NSPC can act synergistically to promote
tumor progression with severe hemorrhage.
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It has been shown that transplantation of neural stem/progenitor cells
(NSPCs) has potential as a therapy for various disorders of the central
nervous system, such as stroke [1], multiple sclerosis [2], Parkinson
disease [3], Huntington disease [4], amyotrophic lateral sclerosis [5],
and gliomas [6–9]. NSPCs tend to migrate toward injured regions in
these various brain pathologies [1,2,4,7–9]; this migration is
regulated mainly by the signaling axis of C-X-C motif chemokine
12 (CXCL12) and its receptor C-X-C chemokine receptor type 4
(CXCR4) [10]. NSPCs move along the CXCL12 concentration
gradient formed by the increased levels at sites of injuries [11–13],
resulting in targeted migration [10,13–15].
Targeted migration of NSPCs to lesion sites is essential for the
direct repair of damaged tissues. Therefore, the promotion of that
migratory behavior through manipulation of CXCL12 signaling
has been proposed as a therapeutic strategy, whereby transplanted
cells would facilitate recovery processes [15–20]. In support of this,treatments that block CXCL12 signaling were found to result in a
marked impairment of migration and proliferation of the engrafted
NSPCs [14]. Furthermore, locally administered CXCL12 stimu-
lates the recruitment of stem/progenitor cells, which promotes
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improvement of Alzheimer disease [19], skeletal regeneration
[16], and wound healing [17].
The first clear demonstration that NSPCs could exhibit migratory
activity toward the site of a brain tumor was provided by Aboody and
colleagues [9]. NSPCs have the potential to specifically target the sites
of brain tumors [9] and could thus be used as therapeutic vehicles
[21]. If the targeted migration of NSPCs could be accelerated by
promoting CXCL12 signaling, this would make NSPCs particularly
useful in cell-based brain tumor therapy. However, the strategy of
promoting migratory behavior in brain tumors by the manipulation
of CXCL12 signaling has not been examined in vivo previously. To
assess the effects of this strategy on brain tumors, this study used
magnetic resonance imaging (MRI) to monitor the pathologic
changes of brain tumors in vivo following combined treatment with
NSPC implantation and CXCL12 facilitation.
The effects of treatments on the natural development of glioma
were investigated using a model of spontaneous brain tumor in
which rats develop various gliomas several months after transpla-
cental administration of N-ethyl-N-nitrosourea (ENU) as de-
scribed previously [22–24]. Furthermore, the immune rejection
responses of the xenografts [25] were minimized by using the same
species of NSPCs as that used in the ENU-induced rat brain
tumor model. The tumorigenic potential of immortalized cells
[26–28] was avoided by applying NSPCs from primary cultures.
The locations of cells were determined by injecting green
fluorescent protein (GFP)–expressing NSPCs (GFP-NSPCs)
from GFP-expressing transgenic rats intraventricularly into the
brain of tumor-bearing rats. Simultaneously, these rats received an
intracerebral injection of CXCL12 near to the tumor sites to
promote NSPC migration.
MRI was applied because it allows repeated imaging with a high
spatial resolution; MRI can provide accurate tumor volume
measurements and morphologic information over longitudinal time
points and can thus be used to evaluate the effects of cell therapies
[29]. T2-weighted MRI images (T2WIs) were acquired to measure
tumor volumes and monitor the tumor morphology [30] for 42 days
after surgery. T2WIs further confirmed the histologic features of the
gliomas following the treatments. The findings of this study suggest
that CXCL12 is an effective chemoattractant that facilitates the
tumor-targeted migration of exogenous NSPCs and that CXCL12
and NSPC can act synergistically to promote tumor progression with
severe hemorrhage.
Materials and Methods
Animals
Eleven pregnant Sprague-Dawley rats (the National Laboratory
Animal Center of Taiwan, Taipei, Taiwan) and 27 of their 118
offspring were used for the tumor model in this study. In total, 70
neonatal GFP-expressing transgenic rats (“green rat” CZ-004, SD-
Tg(Act-EGFP) CZ-004Osb; Japan SLC, Shizuoka, Japan) were
used for harvesting the primary NSPCs. The animals were housed
in a well-controlled environment with a 12-hour/12-hour light/
dark cycle and controlled humidity and temperature. Rats were
triple housed in plastic cages with ad libitum access to food and
water. All experimental procedures were approved by the Institute
of Animal Care and Utilization Committee at Academia Sinica
(Taipei, Taiwan).The ENU-Induced Brain Tumor Model
The pregnant Sprague-Dawley rats were placed into a restrainer
and injected intraperitoneally with 50 mg/kg ENU (Sigma-Aldrich,
St Louis, MO) at 18 days of gestation using a 26-gauge needle for
several minutes. MRI was applied to 120-day-old offspring to confirm
the location and size of the tumors. Rats with similar-sized tumors
(~1 mm3) near the corpus callosum were selected for experiments.
Rats with trigeminal neurinoma and pituitary tumors or with obvious
physiological defects were excluded from this study.
Harvesting and Culturing of Primary GFP-NSPCs
GFP-NSPCs were harvested from both lateral walls of the ventricle
in neonatal GFP-expressing transgenic rats and cultured as described
elsewhere [31,32]. In brief, pooled tissues isolated from the lateral
walls were dissociated by mechanical trituration in NSPC medium,
which consists of Dulbecco's modified Eagle's medium/F12
(Invitrogen/Gibco BRL, Grand Island, NY) with 0.3% glucose,
23 μg/ml insulin, 92 μg/ml apotransferrin, 55 μMputrescine, 25 nM
sodium selenite, 6.28 ng/ml progesterone, 20 ng/ml epidermal
growth factor, and 20 ng/ml fibroblast growth factor. The cells were
then counted and plated at a density of 1.5 × 106 cells in T75 flasks
(Orange Scientific, Brussels, Belgium) with 20 ml of medium. The
cultures were replenished with 20 ml of NSPC medium every
2 days. The cultures were maintained at 37°C in a humidified
atmosphere of 5% CO2/95% air. At 5 to 7 days after isolation, the
cells grew as free-floating neurospheres, which were dissociated into
single cells for transplantation when they reached diameters of 140
to 160 μm.
GFP-NSPC Implantation and Local CXCL12 Administration
The rats were randomly assigned to the following treatment
groups: 1) NSPC only (n = 6), 2) CXCL12 only (n = 6), 3) CXCL12-
NSPC (n = 6), and 4) sham (n = 6). The animals were anesthetized
with chloral hydrate (450 mg/kg; Sigma-Aldrich) and positioned in a
stereotaxic apparatus. In the case of GFP-NSPC transplantation
(i.e., NSPC and CXCL12-NSPC groups), the cells were freshly
prepared [1 × 106 in 5 μl of phosphate-buffered saline (PBS), pH 7.4]
and implanted into the lateral ventricle ipsilateral to the site of tumors
(bregma = –0.5 mm; lateral = –1.5 or 1.5 mm; and depth = 3.5 mm)
using a 10-μl Hamilton syringe with a 30S-gauge needle at a rate of
0.5 μl/min. The following doses of CXCL12 (Sigma-Aldrich) had
been tested in a pilot study: 0.2, 1, and 2 μg/μl. The tumor
promotion effect was greater for tumors treated with 1 μg/μl
CXCL12 and NSPCs, and hence, 1 μg/μl CXCL12 in 5 μl of PBS
(pH 7.4) was selected for use in this study. In the CXCL12-NSPC
and CXCL12-only groups, a solution of CXCL12 was injected
stereotaxically near the tumor sites using the same surgical procedure
as described above.
Magnetic Resonance Imaging
The animals underwent five MRI examinations, with the same
imaging procedure being followed for every time point. Images were
acquired at 0, 1, 14, 28, and 42 days after injections (no data are shown
herein for the 1-day time point). All MRI examinations were
performed using a horizontal 7.0-T spectrometer (PharmaScan 70/16;
Bruker, Ettlingen, Germany) with an active shielding gradient of 300
mT/m in 80 microseconds. The animals were anesthetized with 2%
isoflurane in O2 at a flow rate of 1 l/min. The breathing rate was
maintained at between 60 and 70 breaths per minute. The
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immobilized with ear bars to minimize movement artifacts. T2WIs
were acquired with the following parameters: field of view = 3 cm; slice
thickness = 1 mm; 28 slices; repetition time = 5100 milliseconds; echo
time = 70milliseconds; echo train length = 8; number of excitations = 6;
and matrix size = 256 × 256. These images were used to measure the
tumor volume and to monitor the tumor morphology.
Data Analysis
The outlines of the tumors were delineated on the basis of the
contrast provided by the T2WIs between the tumor and the brain
tissues. The total tumor volume was calculated by summing the
tumor area in three dimensions using Avizo software (version 6.0;
Visualization Sciences Group, Burlington, MA). Growth curves were
plotted as the change in tumor volume at each time point relative to
the baseline volume. The hypointense area was selected manually on
the T2WIs. The total hypointense volume was calculated by summingB
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Figure 1. The combination of CXCL12 elevation and GFP-NSPC transp
representative axial T2WIs from the CXCL12-NSPC (n = 6), CXCL12-on
days 0, 14, 28, and 42 after tumor detection is shown. Red arrows indic
the tumor volume was significantly greater in the CXCL12-NSPC grouthe hypointense areas in three dimensions using Avizo software. The
ratio of the intratumoral hypointense area was then calculated by
dividing the intratumoral hypointense volume by that of the entire
tumor region.
Histologic Examination
To correlate MRI signal changes with histologic data, animals were
perfused transcardially with 4% paraformaldehyde (Sigma-Aldrich) in
PBS (pH 7.4) immediately after the scanning performed at the last time
point. The brains were removed from the cranium, kept in the same
fixative overnight at 4°C, and then sectioned at a thickness of 50μmusing
a cryostat (CM 3050S; Leica Microsystems, Wetzlar, Germany). The
brain sections were stained using hematoxylin and eosin (H&E) to
confirm whether the signal changes detected on the T2WIs were indeed
induced by the pathologic conditions, such as necrosis and hemorrhage
within the tumor. Primary antibodies raised againstCXCL12 (SantaCruz
Biotechnology, Santa Cruz, CA), CXCR4 (Santa Cruz Biotechnology),Day28 Day42
**
***
Day 28 Day 42
12-NSPC
12-only
-only
lantation promoted ENU-induced brain tumor growth. (A) A series of
ly (n= 6), NSPC-only (n= 6), and sham (n = 6) groups acquired on
ate the tumor location. (B) Tumor growth curve. On days 28 and 42,
p than those in each of the other groups (**P b .01 and **P b .001).
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International) were used to examine the expression patterns of the
chemokine and its receptor and the location of GFP-NSPCs and to
confirm the neuronal lineage of the GFP-NSPCs.
Due to high tissue autofluorescence, two chromogens—nickel-
intensified DAB and DAB—were used for immunohistochemistry in
this study. Free-floating sections were treated with 0.2% H2O2 in
PBS containing 0.3% Triton X-100 to inhibit endogenous peroxidase
staining. Nonspecific binding was blocked by incubating sections in
blocking solutions for 1 hour. BSA was used at specific concentrations
in PBS with 0.3% Triton X-100 as the blocking solution for the
various primary antibodies: 1% BSA for CXCL12, 3% BSA for
CXCR4 and GFP, and 1.2% BSA for NeuN. The sections were
subsequently incubated with diluted primary antibodies (1:200 for
CXCL12, 1:200 for CXCR4, 1:1000 for GFP, and 1:400 for NeuN)
overnight at room temperature, washed in PBS with 0.3% Triton X-
100, and then placed into solutions of the corresponding biotinylated
secondary antibodies (1:500, goat anti-rabbit antibody or donkey
anti-goat antibody; Jackson ImmunoResearch Laboratories, WestNSPC onlySham
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Figure 2. A significant increase in the degree of intratumoral hemorrh
of CXCL12 and GFP-NSPCs. (A) In T2WIs, severe signal loss (red arro
(B) H&E staining was used to confirm the source of the changes in
sections are shown. (D) The ratio of intratumoral hemorrhagic area w
groups (***P b .001).Grove, PA) for 1 hour. After washing, the sections were exposed to
avidin-biotin-peroxidase complex (1:500; ABC Elite kit; Vector
Laboratories, Burlingame, CA) for 1 hour at room temperature and
then stained with 0.025% DAB, 1.5% nickel ammonium sulfate, and
0.024%H2O2 in PBS for 5 to 10minutes until the desired dark-purple
coloration had developed. To double-stain with GFP, the same
procedures were employed for sections withNeuN staining as described
above but without the 1.5% nickel ammonium sulfate in the
development step, resulting in the development of a brown coloration.
The sections were then washed, mounted on coated slides, dehydrated,
and coverslipped with dibutyl phathalate xylene (DPX) mounting
solution (Sigma-Aldrich).
Statistical Analysis
All data are presented as mean ± SEM values. Between-group
differences in tumor volume, the ratio of hypointense areas, and
numbers of GFP-positive (GFP+) cells and GFP+/NeuN-positive
(NeuN+) cells were tested with analysis of variance, followed by
Fisher post hoc tests. All statistical analyses were performed usingCXCL12-NSPCCXCL12 only
200 µm
1000 µm
***
***
*
age was found in tumors from brains treated with the combination
w) was found in tumors from the CXCL12-NSPC group on day 42.
MRI signal in the tumor tissue. (C) Enlarged views of H&E-stained
as significantly higher in the CXCL12-NSPC group than in all other
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significance was set at P b .05.
Results
The Combination of CXCL12 and GFP-NSPCs Promotes
ENU-Induced Brain Tumor Growth
Tumor volumes were determined by analyzing T2WIs at 0, 14, 28,
and 42 days after injections (Figure 1A). The curves of relative tumor
growth show that the tumors in the CXCL12-NSPC group grew
faster than those in all other groups (Figure 1B). At days 28 and 42,
the relative tumor volume was significantly larger in the CXCL12-
NSPC group than in the other groups (Figure 1B) and did not differ
significantly among the CXCL12-only, NSPC-only, and sham
groups at any of the time points [analysis of variance: F(6,40) =
14.5, P b .0001; Fisher post hoc tests: all P values b .01 for CXCL12-
NSPC vs any of the other groups at day 28 and all P values b .001 for
CXCL12-NSPC vs any of the other groups at day 42]. A limited
effect was found when either CXCL12 or GFP-NSPCs were given
alone, but a significant degree of tumor promotion in ENU-induced
brain tumors was only found after administration of the combination
of CXCL12 and GFP-NSPCs.
The Combination of CXCL12 and GFP-NSPCs Increases the
Severity of Intratumoral Hemorrhage
Severe signal loss on T2WI was observed in tumors of the
CXCL12-NSPC group on day 42 but not in the tumors of theH&E
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Figure 3. Immunohistochemical staining for CXCL12 and CXCR4
immunoreactivities were both strong in tumors from the CXCL12-N
undetectable in the NSPC-only and sham groups.other groups (Figure 2A). H&E staining indicated that this signal
loss was attributable to intratumoral hemorrhage (Figure 2B). As
shown in Figure 2C (magnified views of Figure 2B), an extensive
area of hemorrhage (bright pink color on H&E staining) is clearly
observed in the CXCL12-NSPC group. The hypointense areas
were measured, and the ratios of the intratumoral hypointense
areas were then calculated (Figure 2D). The ratio of the
hypointense area to that of the entire tumor region was
significantly higher in the CXCL12-NSPC group than in the
other groups (P b .001).
Increased CXCL12 and CXCR4 Expression Following Combined
GFP-NSPC and CXCL12 Treatments
The expression levels of CXCL12 and CXCR4 in the tumors of the
four treatment groups were examined by immunohistochemistry
(Figure 3). Strong CXCL12 and CXCR4 expressions were detected in
the CXCL12-NSPC group (Figure 3, CXCL12 and CXCR4). In
addition, moderate CXCL12 and slight CXCR4 expressions were
observed in the CXCL12-only group. The expression levels of
CXCL12 and CXCR4 were either low or undetectable in the NSPC-
only and sham groups.
Histologic Evidence of GFP-NSPC–Targeted Migration into
the Glioma Region
The grafted GFP-NSPCs in the brains of animals in the CXCL12-
NSPC and NSPC-only groups were identified by immunohisto-
chemistry (Figure 4A, GFP). No GFP immunoreactivity was found in200 µm
CXCL12 CXCR4
in tumors from the four treatment groups. CXCL12 and CXCR4
SPC group, moderate in those from the CXCL12-only group, and
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Figure 4. Numerous GFP-NSPCs were found in the CXCL12-NSPC group. (A) GFP immunohistochemical staining was employed in tissue
samples obtained from all treatment groups to identify the locations of the GFP-NSPCs. (B) Diagrammatic representation of the
distribution of GFP+ cells in the CXCL12-NSPC group. The grafted cells were found on the tumor border and in the tumor mass. (C) The
number of GFP+ cells was significantly greater in the CXCL12-NSPC group than in the NSPC-only group (**P b .01).
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NSPC transplantation was not employed in these groups. GFP+ cells
were widespread in the tumors of the CXCL12-NSPC group, but
only a few GFP+ cells were observed in the tumors of the NSPC-only
group. A representative diagram of the distribution of GFP+ cells in
the tumors of the CXCL12-NSPC group is shown in Figure 4B, in
which each red dot represents two or three GFP+ cells. The number
of GFP+ cells that had migrated toward tumor sites differed500 µm 20 µm
A
Figure 5. Neuronal phenotype of the GFP-NSPCs in the CXCL12-NS
NeuN. Light microscopy of double immunohistochemical staining
demonstrates that most of the cells express both GFP and NeuN. (B) T
CXCL12-NSPC and NSPC-only groups (**P b .01).significantly between the CXCL12-NSPC (1159 ± 341 cells) and
NSPC-only (45.7 ± 19.8 cells) groups (P b .01; Figure 4C).
Phenotypic Characterization of GFP-NSPCs
The grafted cells identified by GFP staining exhibited neuronal-
like morphology with extended neurites (Figure 4A, magnified images
from the CXCL12-NSPC and NSPC-only groups). Double labeling
with NeuN (which is a neuronal marker) and GFP was employed toB
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PC group. (A) Double immunohistochemical staining of GFP and
for GFP (dark purple) and the neuronal marker NeuN (brown)
he number of GFP+/NeuN+ cells differed significantly between the
Table 1. Numbers of GFP+/NeuN-Negative (NeuN–), GFP+/NeuN+, and GFP-Negative (GFP–)/
NeuN+ Cells in the CXCL12-NSPC and NSPC-Only Groups.
No. of Cells
CXCL12-NSPC NSPC Only
GFP+ GFP+/NeuN– 209.8 ± 107.8 28.7 ± 16.2
GFP+/NeuN+ 948.7 ± 257.7 17.0 ± 14.6
GFP– *GFP–/NeuN+ 244.2 ± 81.9 13.7 ± 12.3
* Few GFP–/NeuN+ cells were found in the CXCL12-only and sham groups (data not shown).
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NeuN+ double staining demonstrated that ~80% of the GFP+ cells
expressed NeuN in the tumors of the CXCL12-NSPC group (see
Table 1). The number of GFP+/NeuN+ cells in the tumor regions
(Figure 5B) differed significantly between the CXCL12-NSPC (949 ±
258 cells) and NSPC-only (17.0 ± 14.6 cells) groups (P b .01;
Figure 5B). Only a few NeuN+ cells were found in the CXCL12-only
and sham groups (data not shown).
Discussion
The targeted migration of stem cells is essential for the direct repair of
injured tissues. Several studies have found that a strategy involving
promoting CXCL12, which is a major signaling factor in NSPC
migration, enhanced the migration of transplanted cells toward lesion
sites [15–20]. The effects of this strategy on brain tumors had not
been examined previously; the present study has demonstrated that
this strategy elicits a striking tumor-promoting effect. The local
administration of CXCL12 boosts the CXCL12-directed migration
of grafted NSPCs toward the sites of ENU-induced brain tumors.
However, enhanced tumor outgrowth and increased intratumoral
hemorrhage were found in tumors receiving the combined CXCL12-
NPSC treatment (Figures 1 and 2). Accordingly, under CXCL12
facilitation, NSPC may play a role in promoting tumor progression.
The role of NSPCs in brain tumor growth remains controversial.
There are reports that unmodified and endogenous neural
precursors can inhibit tumor outgrowth [6,33]. However, the
potential of NSPC transformation [34,35] and their involvement in
tumor development [36] have long been considered. Clinically, it
has also been shown that gliomas covering the subventricular zone
had a worse prognosis for patients, indicating the tumorigenic
potential of NSPCs [37,38]. These findings suggest that NSPCs
exert adverse effects under certain circumstances.
Hemorrhage is a rupture of blood vessels that results in the release
of blood cells and other blood-borne substances into the surrounding
tissues. Intratumoral hemorrhage is commonly seen in malignant
brain tumors, and the etiology of hemorrhage has been attributed to
factors such as hypervascularity, abundant microvessel proliferation,
unstable vascular structures, blood-brain barrier disruption, and
necrosis with release of intracellular proteolytic enzymes due to rapid
tumor growth [39]. Necrosis of the tumor can cause a direct
breakdown of vessels in the tumor regions including pre-existing and
newly formed vessels and subsequent hemorrhage [40]. The results of
H&E staining strongly suggest that hypointense areas are attributable
to intratumoral hemorrhage (Figure 2). The present study found a
significant increase in intratumoral hemorrhage in tumors that had
received the combined CXCL12-NPSC treatment (Figure 2),
illustrating the potential role of this strategy in rapid tumor
progression, which eventually causes necrosis and intratumoral
hemorrhage. Compared to all other groups, tumors in theCXCL12-NSPC group exhibited the largest hemorrhagic areas and
the highest level of CXCL12 (Figures 2 and 3). CXCL12 induces
basement membrane degradation [41], promotes proliferation of
endothelial [42] and glioma [43] cells, and increases the permeability
and disruption of the blood-brain barrier [44], suggesting that the
level of CXCL12 is closely associated with the grade of hemorrhage.
Stronger migratory responses of NSPCs were associated with
higher levels of chemokine at targeted sites. CXCL12 may have
formed a strong gradient that attracted a large number of grafted
NSPCs toward tumors of the CXCL12-NSPC group (Figure 4). In
addition, CXCL12 may promote the survival of NSPCs as an
alternative explanation for why more of these cells were detected in
the combined treatment group [45]. No therapeutic effect of NSPC
transplantation alone on brain tumors was observed in the present
study. This may be due to only a few NSPCs migrating toward sites of
ENU-induced brain tumors with low or undetectable CXCL12 levels
to exert tumor-inhibitory functions (Figure 3). Stronger CXCL12
and CXCR4 expressions were detected in the CXCL12-NSPC group
than in the CXCL12-only group (Figure 3, CXCL12 and CXCR4),
which may have resulted from the interaction between NSPCs and
CXCL12. When the level of CXCL12 is high, it has been shown to
act synergistically with NSPCs [46,47] to upregulate CXCL12/
CXCR4 signaling of astrocytes [48], endothelial cells [49,50], and
tumor cells [51]. The scarce CXCR4 expression in the CXCL12-only
group is probably attributable to CXCL12 alone at the given dose not
forming a gradient that was sufficiently strong to attract CXCR4-
expressing cells toward tumor sites. In contrast, the combination of
CXCL12 and NSPC exerted significant effects in recruiting CXCR4-
expressing cells into the tumor, thereby elevating CXCR4 levels at the
tumor site. Furthermore, CXCL12 not only elicits migratory
responses but also increases the proliferation [10] and CXCR4
expression [46] of grafted NSPCs. The grafted NSPCs would be
activated by CXCL12, and the NSPCs may tend to be closely
associated with endothelial cells and astrocytes (which express
CXCR4), which would support their survival and growth
[10,52,53]. This is another possible source of the CXCR4 expression
seen in the CXCL12-NSPC group.
The chemokine CXCL12 and its cell surface receptor CXCR4 are
vital mediators of NSPC migration toward brain tumors. Murine
NSPCs inoculated into established intracranial GL26 tumors have
demonstrated significant tumor-specific migration away from the site
of inoculation to the proximity of the disseminating tumor cells [54].
Cells that had demonstrated tumor-tracking behavior showed
significant staining for CXCR4. In the same study, both murine
and human fetal NSPC migration toward tumor-conditioned
medium could be impaired by using anti-CXCL12 and anti-
CXCR4 neutralizing antibodies. Intravascularly injected murine
NSPCs have been shown to migrate to and infiltrate subcutaneous
and intracranial glioma tumors in nude mice [55]. CXCL12
expressed by a tumor-derived endothelium may attract NSPCs to
migrate to the site of the tumor [53,56]. Furthermore, NSPC-to-
glioma tropism was increased through up-regulation of CXCR4 on
NSPCs and CXCL12 on glioma cells under a hypoxic condition [57].
All of these findings indicate the importance of CXCL12 and CXCR4
in the tumor-specific migration of NSPCs.
The fate of grafted NSPCs in the brain tumors is for them to
remain in a quiescent and undifferentiated state [9,58,59]. However,
contrary to these previous reports, most of the grafted cells migrating
to tumors with CXCL12 facilitation in the present study were found
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reasons for the contradictory findings are the species from which the
NSPCs originated (rat in this study and human or mouse in the
aforementioned studies) and the high levels of CXCL12 used in the
present study. Unlike mouse and human NSPCs, which can be
maintained for a long period of time in vitro without genetic
modifications, rat NSPCs derived from the subventricular zone or
hippocampal subgranular zone typically sustain proliferation for only
a relatively short time and have a tendency to differentiate [60,61]. In
addition, local administration of CXCL12 may create a distinct local
environment that stimulates NSPCs to differentiate into neurons.
CXCL12 was shown to promote neuronal survival and the
differentiation of NSPCs to support neural tissues [15,62] and to
stimulate neurite outgrowth and axonal branching of cultured
neuronal cells [63,64], indicating its role in controlling neuronal
differentiation. Together, these results indicate that rat NSPCs, which
tend to differentiate, may respond to CXCL12 induction and, as a
result, differentiate into neurons.
It has recently been reported that the expressions of neuronal markers
in brain tumorsmay be associated with a poor outcome [65–67]. NeuN
was noted to be present in various types of high-grade and recurrent
gliomas [65,66]. Multiple neuronal immunomarker expressions in
glioma were associated with a poor survival rate [67]. We have
demonstrated herein that ~80% of grafted cells migrating toward
tumors with the combined CXCL12-NPSC treatment differentiated
into neurons (Figures 4 and 5). The present results show that the
increased number of neurons in tumors was associated with increased
tumor volume. However, the roles of such an increased number of
tumor neurons remain unclear.
The strategy of using exogenous CXCL12 to promote NSPC
migration in brain tumors was found in the present study to be
associated with a higher rate of tumor growth and an increase in
intratumoral hemorrhage. These grafted NSPCs that migrated toward
the tumors tended to differentiate into neurons due to the known
differentiation potential of rat NSPCs and induction by CXCL12. In
conclusion, the results of the present study are especially important in
that they illustrate possible effects of stem cell therapies on brain
tumors. That is, the strategy of further promoting targeted NSPC
migration by CXCL12 may lead to adverse effects.
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